Bernhard Lämmle

Q: What Schools Are Affiliated With Bernhard Lämmle

Bernhard Lämmle is affiliated with the following schools: University College London, ETH Zurich, University of Basel, University of Bern, University of Zurich, Harvard University

Bernhard Lämmle's AcademicInfluence.com Rankings

Bernhard Lämmle

Computer Science

#7711

World Rank

#8116

Historical Rank

Computational Linguistics

#1593

World Rank

#1610

Historical Rank

Machine Learning

#2945

World Rank

#2982

Historical Rank

Artificial Intelligence

#3239

World Rank

#3287

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Bernhard Lämmle's Degrees

PhD Computer Science ETH Zurich
Masters Computer Science University of Zurich
Bachelors Computer Science University of Zurich

Similar Degrees You Can Earn

Why Is Bernhard Lämmle Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bernhard Lämmle's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. (1998) (1596)
Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. (1996) (890)
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. (2003) (667)
Survival and relapse in patients with thrombotic thrombocytopenic purpura. (2010) (498)
von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. (2011) (374)
Deficient Activity of von Willebrand Factor–Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura (1997) (365)
Severe COVID-19 infection associated with endothelial activation (2020) (363)
Partial amino acid sequence of purified von Willebrand factor-cleaving protease. (2001) (356)
Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. (1998) (326)
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies (2017) (325)
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. (2007) (325)
This article has been cited by other articles (2003) (323)
Assay of von Willebrand Factor (vWF)-cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWF (1999) (323)
The incidence of thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS‐13 deficiency (2005) (312)
Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. (2002) (311)
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. (2005) (275)
Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. (2001) (269)
Elevated nucleosome levels in systemic inflammation and sepsis* (2003) (244)
Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. (2012) (238)
Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). (2002) (223)
Association of two silent polymorphisms of platelet glycoprotein la/lla receptor with risk of myocardial infarction: a case-control study (1999) (217)
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. (2004) (216)
Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. (1997) (196)
Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura (1999) (190)
Thromboembolism and Bleeding Tendency in Congenital Factor XII DeficienCy - A Study on 74 Subjects from 14 Swiss Families (1991) (180)
ADAMTS‐13, von Willebrand factor and related parameters in severe sepsis and septic shock (2007) (159)
Thrombotic Risk of Women with Hereditary Antithrombin III-, Protein C- and Protein S-Deficiency Taking Oral Contraceptive Medication (1994) (154)
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. (2005) (151)
Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. (2013) (149)
Thrombotic thrombocytopenic purpura (2017) (144)
Reevaluation of the Incidence of Thromboembolic Complications in Congenital Factor XII Deficiency (1999) (136)
Ten years of prophylactic treatment with fresh‐frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor‐cleaving protease (2001) (120)
Plasma DNA is Elevated in Patients with Deep Vein Thrombosis. (2013) (113)
Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura (2009) (110)
Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. (1999) (109)
ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor‐cleaving protease activity by recombinant human ADAMTS13 (2003) (106)
Impaired DNase1‐mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies (2015) (103)
Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. (1986) (101)
Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2. (2017) (99)
C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction (2002) (98)
Measurement of von Willebrand factor‐cleaving protease (ADAMTS‐13) activity in plasma: a multicenter comparison of different assay methods (2003) (93)
Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis (1997) (89)
von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. (2004) (89)
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic‐uremic syndromes (2010) (88)
Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor‐cleaving protease (2001) (86)
Measurement of ADAMTS‐13 activity in plasma by the FRETS‐VWF73 assay: comparison with other assay methods (2006) (84)
Von Willebrand Factor in Thrombotic Thrombocytopenic Purpura (1999) (84)
Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. (1993) (83)
Accuracy of d‐dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study (2003) (81)
Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. (2012) (80)
Initial experience from a double‐blind, placebo‐controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura (2012) (78)
Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. (2017) (78)
Thrombotic thrombocytopenic purpura (2005) (77)
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. (2007) (77)
Protein Z in ischaemic stroke (2001) (76)
Cognitive deficits after recovery from thrombotic thrombocytopenic purpura (2009) (75)
Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism (2013) (75)
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura (2012) (74)
A common origin of the 4143insA ADAMTS13 mutation (2006) (73)
The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017 (2019) (72)
Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome, 1996 to 2011 (CME) (2012) (71)
Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. (1996) (71)
Fifteen Coagulation and Fibrinolysis Parameters in Diabetes Mellitus and in Patients with Vasculopathy (1984) (70)
Platelets: thrombotic thrombocytopenic purpura. (2002) (70)
Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. (2003) (70)
ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients (2020) (69)
Hyperbilirubinemia interferes with ADAMTS‐13 activity measurement by FRETS‐VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies (2007) (67)
Von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome (2001) (67)
Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. (2004) (66)
Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. (2004) (65)
Sporadic bloody diarrhoea‐associated thrombotic thrombocytopenic purpura‐haemolytic uraemic syndrome: an adult and paediatric comparison (2008) (63)
Frequency of protein Z deficiency in patients with ischaemic stroke (2001) (63)
D-Dimers Predict Stroke Subtype when Assessed Early (2009) (62)
Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). (1984) (61)
Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. (2002) (60)
Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients (2012) (60)
Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism (2015) (58)
Immunoblotting studies of the molecular forms of protein C in plasma. (1988) (58)
Mutations in the human factor XII gene. (1997) (58)
Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis (2020) (58)
Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13) (2008) (58)
The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology (2013) (57)
Protein C replacement in severe meningococcemia: rationale and clinical experience. (2001) (56)
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management (2021) (55)
ADAMTS13 activity in sickle cell disease (2006) (53)
Protein Z in healthy human individuals and in patients with a bleeding tendency (1998) (53)
Treatment of thrombotic thrombocytopenic purpura (1983) (53)
Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. (2002) (51)
Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. (2002) (51)
Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. (2014) (51)
Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. (2002) (50)
Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353-->Pro leading to loss of a kallikrein cleavage site. (1994) (50)
Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems (2003) (50)
Von Willebrand factor – cleaving protease ( ADAMTS 13 ) in thrombocytopenic disorders : a severely deficient activity is specific for thrombotic thrombocytopenic purpura (2002) (50)
Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. (2009) (49)
Formation of the fibrin clot: the balance of procoagulant and inhibitory factors. (1985) (47)
Rapid D-dimer testing and pre-test clinical probability in the exclusion of deep venous thrombosis in symptomatic outpatients (2001) (47)
Factor XII clotting activity and antigen levels in patients with thromboembolic disease (1992) (47)
High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence (2016) (46)
No association of APC resistance with myocardial infarction. (1995) (45)
16 Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura (1998) (45)
The Oklahoma Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome Registry: the Swiss connection (2008) (44)
Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory. (2003) (44)
SimpliRED D-dimer Assay: Comparability of Capillary and Citrated Venous Whole Blood, Between-assay Variability, and Performance of the Test for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients (1998) (44)
Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. (2004) (42)
Is Plasminogen Deficiency a Thrombotic Risk Factor ? – A Study on 23 Thrombophilic Patients and their Family Members (1998) (41)
A frameshift mutation in Exon V of the A alpha-chain gene leading to truncated A alpha-chains in the homozygous dysfibrinogen Milano III. (1994) (41)
Mycobacterium genavense infection in a patient with long‐standing chronic lymphocytic leukaemia (2000) (39)
Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. (2012) (39)
The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. (2014) (39)
Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry (2013) (38)
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. (2020) (37)
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. (2009) (37)
Platelet Aggregation, β-Thromboglobulin and Platelet Factor 4 in Diabetes Mellitus and in Patients with Vasculopathy (1984) (36)
Plasma protein C inhibitor is elevated in survivors of myocardial infarction. (1997) (36)
Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI (1988) (35)
Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III. (1980) (35)
Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura--new insights into underlying biochemical mechanisms. (2000) (34)
Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease (2008) (34)
Depression and cognitive deficits as long‐term consequences of thrombotic thrombocytopenic purpura (2017) (33)
Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis (2007) (33)
Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. (2007) (32)
Prospective comparison of clinical prognostic scores in elder patients with a pulmonary embolism (2012) (32)
Heparin-dependent in vitro aggregation of normal platelets by plasma of a patient with heparin-induced skin necrosis: specific diagnostic test for a rare side effect. (1988) (31)
Purified Human Plasma Kallikrein Does Not Stimulate but Primes Neutrophils for Superoxide Production (1989) (31)
Enhanced specificity of immunoblotting using radiolabeled antigen overlay: studies of blood coagulation factor XII and prekallikrein in plasma. (1986) (30)
Low molecular weight heparin‐induced thrombocytopenia and skin necrosis distant from injection sites (1994) (30)
Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network. (1994) (30)
Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. (1998) (29)
Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency (2011) (29)
Thromboembolism in patients with congenital afibrinogenaemia (2016) (29)
Circulating extracellular DNA is an independent predictor of mortality in elderly patients with venous thromboembolism (2018) (29)
New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review (1999) (29)
The novel acceptor splice site mutation 11396(G-->A) in the factor XII gene causes a truncated transcript in cross-reacting material negative patients. (1995) (28)
Factor XIII in severe sepsis and septic shock. (2007) (27)
Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. (2002) (27)
Variability of anti‐PF4/heparin antibody results obtained by the rapid testing system ID‐H/PF4‐PaGIA (2009) (27)
The von Willebrand Factor-Cleaving Protease (ADAMTS-13) and the Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP) (2003) (27)
Quantitative Immunoblotting of Plasma and Platelet Protein S (1986) (25)
Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. (2001) (25)
A new substitution, gamma 358 Ser-->Cys, in fibrinogen Milano VII causes defective fibrin polymerization. (1994) (25)
A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13 (2008) (24)
Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy. (2015) (24)
Usefulness of the D‐dimer/fibrinogen ratio to predict deep venous thrombosis (2005) (24)
1,25(OH)2 vitamin D3 in osteoporosis--a pilot study. (1979) (23)
Contact phase of blood coagulation is not activated in edema of high altitude. (1989) (22)
Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10) (2001) (22)
Quantitative immunoblotting assay of blood coagulation factor XII. (1986) (22)
Performance of a New Fibrin Monomer Assay to Exclude Deep Vein Thrombosis in Symptomatic Outpatients (1999) (21)
Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin–α2-antiplasmin complex is an independent predictor of coronary re-events (2001) (21)
Influence of Low Molecular Weight Heparin and Low Molecular Weight Dextran Sulfate on the Inhibition of Coagulation Factor XIa by Serpins (1998) (21)
Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab (2018) (20)
The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications (2014) (20)
Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study (2016) (20)
Amidolytic activity in normal human plasma assessed with chromogenic substrates. (1979) (20)
Hemophilia A Pseudoaneurysm in a Patient with High Responding Inhibitors Complicating Total Knee Arthroplasty: Embolization: A Cost-Reducing Alternative to Medical Therapy (2006) (20)
Bilateral periorbital ecchymoses (2014) (20)
Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine (2015) (19)
Images in clinical medicine. Capnocytophaga canimorsus sepsis. (2009) (19)
Predictors and Outcomes of Recurrent Venous Thromboembolism in Elderly Patients. (2018) (19)
Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura. (2021) (19)
von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids. Sequential measurements over 4 months in 17 patients. (1990) (19)
Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency (2016) (19)
The Contact Phase of Blood Coagulation in Diabetes Mellitus and in Patients with Vasculopathy (1984) (18)
How high is the true fibrinogen content of fibrinogen standards? (1989) (18)
Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation. (2017) (18)
Cold Promoted Activation and Factor XII, Prekallikrein and C1-Inhibitor (1985) (18)
Subcutaneous low-molecular-weight heparin for treatment of Trousseau’s syndrome (1997) (17)
Functional characterization of an abnormal factor XII molecule (F XII Bern). (1991) (17)
Depressive Symptoms as a Novel Risk Factor for Recurrent Venous Thromboembolism: A Longitudinal Observational Study in Patients Referred for Thrombophilia Investigation (2015) (17)
Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and treatment--introduction. (2004) (17)
Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence (2020) (16)
Fibrinogen Milano V: a congenital dysfibrinogenaemia with a gamma 275 Arg-->Cys substitution. (1994) (16)
[Hemostasis parameters in 55 patients with venous and/or arterial thromboembolisms]. (1989) (16)
Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen. (1987) (16)
Splenectomy in thrombotic thrombocytopenic purpura (2000) (15)
IFNα treatment in systemic mastocytosis (1999) (15)
Agreement of D-dimer Results Measured by a Rapid ELISA (VIDAS) before and after Storage during 24 h or Transportation of the Original Whole Blood Samples (2000) (15)
Functional Characterization of a Variant Prekallikrein (PK Zürich) (1993) (15)
Rumpel–Leede sign in thrombocytopenia due to Epstein–Barr virus‐induced mononucleosis (2010) (15)
Contact system activation in human sepsis - 47kD HK, a marker of sepsis severity? (2008) (15)
High Molecular Weight Kininogen Is Cleaved by FXIa at Three Sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326 (2000) (14)
IFNalpha treatment in systemic mastocytosis. (1999) (14)
Normal Binding of Calcium to Five Fibrinogen Variants with Mutations in the Carboxy Terminal Part of the γ-Chain (1996) (14)
Improved detection of proteolytically cleaved high molecular weight kininogen by immunoblotting using an antiserum against its reduced 47 kDa light chain (1995) (14)
Hemostatic risk factors in ischemic stroke (2003) (13)
A quantitative dot immunobinding assay for coagulation factor XII in plasma. (1990) (13)
Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome. (2019) (13)
Monitoring of Oral Anticoagulation by an Amidolytic Factor X Assay (1980) (13)
Characterization of Five Homozygous ADAMTS13 Mutations in Hereditary Thrombotic Thrombocytopenic Purpura – Towards a Phenotype-Genotype Correlation? (2008) (13)
Plasminogen Deficiency: An Additional Risk Factor for Thrombosis in a Family with Factor V R506Q Mutation? (1996) (13)
Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients. (2011) (12)
Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura (2020) (12)
Anticoagulation Management Practices and Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Clinical Research Study (2016) (12)
Functional Characterization of a Variant Factor XII (F XII Locarno) in a Cross Reacting Material Positive F XII Deficient Plasma (1992) (12)
Heparin Cofactor II: Purification and Antibody Production (1986) (12)
Fibrinogens Bern IV, Bern V and Milano XI: three dysfunctional variants with amino acid substitutions in the thrombin cleavage site of the Aalpha-chain. (1999) (11)
Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+) (2013) (11)
Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS13 deficiency? (2005) (11)
[Measurement of bleeding time and study of thrombocyte aggregation. Standardization of methods, normal values and results in patients with suspected hemorrhagic diathesis]. (1988) (11)
Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients? (2017) (10)
No Evidence for Classic Thrombotic Microangiopathy in COVID-19 (2021) (10)
Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation (2009) (10)
Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? (2005) (10)
The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial (2020) (10)
[Systemic chronic juvenile arthritis (Still's disease) in adults. Review of the literature]. (1983) (9)
Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible for defective fibrin monomer polymerization (1993) (9)
Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene (2014) (9)
Chronic interstitial nephritis in Whipple's disease (1983) (9)
Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP). (2006) (8)
Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes. (2004) (8)
Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. (2003) (8)
Factor VIII (procoagulant activity VIII:C, and antigen VIII:CAg, related antigen VIIIR:Ag and ristocetin cofactor VIIIR:Cof) in intensive care patients with clinically suspected disseminated intravascular coagulation (DIC). (1984) (8)
Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP). (2007) (8)
Decreased Free Protein S Levels in Polycythemia Vera (1990) (8)
[Comparison of Quick/INR values of whole capillary blood (CoaguChek Plus) and venous citrate plasma in patients with and without oral anticoagulation]. (1998) (8)
Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired α2-antiplasmin deficiency associated with AL amyloidosis (2009) (8)
Standardized Management Protocol in Severe Postpartum Hemorrhage: A Single-Center Study (2018) (7)
Different Assessment of Plasmin with Different Substrates (1980) (7)
The ADAMTS13 Gene as the Immunological Culprit in Acute Acquired TTP - First Evidence of Genetic Out-Breeding Depression in Humans. (2007) (7)
Warning: Simplate II -Lack of Standardization in Standardized Bleeding Time Devices (1990) (7)
Assay of Factor XII clotting activity in heparinized plasma. (1983) (7)
Biocompatibility in transfusion medicine. (1996) (7)
c.451dupT in KLKB1 is common in Nigerians, confirming a higher prevalence of severe prekallikrein deficiency in Africans compared to Europeans (2020) (7)
Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated Aα‐chains (1996) (7)
Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura (2014) (7)
Plasma prekallikrein determination. (1982) (6)
[Patient self-monitoring of oral anticoagulation with CoaguChek]. (2000) (6)
Treatment with stanozolol before thrombolysis in patients with arterial occlusions. (1985) (6)
[Control of oral anticoagulation: comparison between Quick and colorimetric factor X determination in 107 patients]. (1979) (6)
Major coagulation disorders when using aprotinin--observations on a case. (1991) (6)
Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible for defective fibrin monomer polymerization. (1993) (6)
[Criteria for hemostasis in kidney transplant patients. Comparison of patients undergoing immunosuppression with cyclosporin and azathioprine steroids]. (1984) (6)
Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura. (2021) (5)
In vitro rescue of FGA deletion by lentiviral transduction of an afibrinogenemic patient's hepatocytes (2014) (5)
Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation. (1997) (5)
Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation (2017) (5)
Case 5: Prolonged thrombin time in a patient with multiple myeloma (1999) (5)
Determination of thrombin-antithrombin-III-complex is not a suitable screening test for detecting deficiency of protein C or protein S. (1992) (5)
Venous thrombosis after Caesarean section in a young woman with homozygous APC resistance and type I protein S deficiency (1997) (5)
ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT Study. (2015) (5)
Fibrinogen St. Gallen I (γ 292 Gly → Val): Evidence for Structural Alterations Causing Defective Polymerization and Fibrinogenolysis (1999) (5)
Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation. (2001) (5)
Diagnostic Criteria for Hematopoietic Stem Cell Transplantation-Associated Microangiopathy (TAM): Results of a Consensus Process by an International Working Group. (2005) (5)
Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP). (2006) (4)
Animal models of thrombotic thrombocytopenic purpura: the tales from zebrafish (2020) (4)
The Amidolytic Prekallikrein (PK) Determination: Enhanced PK Activation After Deep-Freezing of Patients' Plasmas (1983) (4)
Cold Agglutinin Syndrome and Liver Transplantation (1994) (4)
Fibrinogen Claro--another dysfunctional fibrinogen variant with gamma 275 arginine-->histidine substitution. (1996) (4)
More on: thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopenia (2005) (4)
Haemorrhagic Shock Nine Days after Extracorporeal Shock Wave Lithotripsy in a Patient with Haemophilia B (1988) (4)
Purified Factor XII Has a Higher Specific Activity than the Parent Molecule in Plasma (1991) (4)
hemoglobin ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by Fatal congenital thrombotic thrombocytopenic purpura with apparent (2013) (4)
A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP) (2010) (4)
Acute pancreatitis and thrombotic thrombocytopenic purpura. (2008) (4)
Methodology and clinical significance of heparin cofactor II. Probable heparin cofactor II deficiency in a patient with cerebrovascular thrombosis. (1985) (4)
[Clinical problems with oral anticoagulation -- 3 case reports]. (2003) (4)
Fibrinogen Milano XIII (Aalpha 19 Arg-->Gly): a dysfunctional variant with an amino acid substitution in the N-terminal polymerization site. (1999) (4)
Immunogold labelling of human von Willebrand factor adsorbed to collagen (1991) (4)
Thrombotic microangiopathy: Caplacizumab accelerates resolution of acute acquired TTP (2016) (4)
[Unexpectedly prolonged thrombin time]. (1993) (4)
[Chronic, hemorrhage-induced iron deficiency anemia in Osler disease]. (1999) (3)
[Comparison of a sensitive rabbit brain thromboplastin and a human placenta thromboplastin for thromboplastin time determination]. (1989) (3)
[Autoimmune polyendocrinopathy with IGA deficiency]. (1978) (3)
May-Thurner syndrome: missed diagnosis and missed early treatment? (2017) (3)
[Thrombotic thrombocytopenic purpura--an often missed diagnosis]. (2014) (3)
Risk stratification of elderly patients with acute pulmonary embolism (2019) (3)
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]. (1999) (3)
Acquired von Willebrand syndrome in myeloproliferative disorder (2003) (3)
Severe Depression Following Recovery From Thrombotic Thrombocytopenic Purpura (TTP) (2012) (3)
[A patient with isolated prolongation of aPTT without hemorrhagic diathesis anamnesis: severe, hereditary factor XII deficiency]. (1999) (3)
DOSING LEPIRUDIN IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA AND VARIOUS DEGREES OF RENAL FUNCTION IMPAIRMENT (2007) (3)
Tryptase from human mast cells does not activate purified human Hageman Factor (1988) (3)
Clinical problems with oral anticoagulant treatment – three case reports (2003) (3)
Case 10: A patient with an isolated prolongation of the activated partial thromboplastin time without a bleeding problem – severe hereditary Factor XII deficiency (1999) (3)
Influence of Personality, Resilience and Life Conditions on Depression and Anxiety in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura (2021) (3)
Fibrinogen Milano XIII (Aα 19 Arg→Gly) (1999) (3)
Factor XII, Plasma Prekallikrein, α2-Macroglobulin and C1-Inhibitor Levels in Renal Allograft Recipients During Immunosuppression with Cyclosporin A – Sequential Measurements over Four Months in 17 Patients (1987) (3)
[Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys]. (1991) (3)
Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (2015) (3)
Thrombotic thrombocytopenic purpura. (2005) (3)
Amidolytic Prekallikrein (PK) Assay: Unsuitability of Cephotest® as an Activator (1984) (3)
[46-year-old woman with multiple hematomas and bleeding of the base of the tongue: phenprocoumon poisoning]. (1999) (3)
purpura Survival and relapse in patients with thrombotic thrombocytopenic (2011) (2)
History of Thrombotic Thrombocytopenic Purpura and the von Willebrand Factor–Cleaving Protease, ADAMTS13 (2015) (2)
Reply to Rebuttal: von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome (2002) (2)
[Contribution of the hemostasis laboratory in the diagnosis of deep venous thrombosis]. (1996) (2)
Case 14: Prolonged prothrombin time, acquired factor X deficiency, hemarthrosis and skin bleeding – Amyloidosis (1999) (2)
Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: Pathophysiology and Differentiation from Graft versus Host Disease (2019) (2)
[Hyperparathyroidism. Quantitative determination of specific skeletal changes in the radiography of the hand]. (1977) (2)
Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies (2020) (2)
167. Nachuntersuchungen bei 100 Patienten mit operativ gesichertem primarem Hyperparathyreoidismus (1978) (2)
A new tool to further explore the role of ADAMTS‐13 in health and disease (2006) (2)
Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities. (2004) (2)
Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker (2021) (2)
Activation of the contact system in patients with sepsis and with septic shock. (1997) (2)
VERLANGERTE THROMBINZEIT - MULTIPLES MYELOM (1999) (2)
[Prevention of venous thromboembolism--in whom, when and how?]. (1994) (2)
Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency (2003) (2)
Anti-ADAMTS13 Inhibitor Boosting During Plasma Exchange Therapy in Acquired TTP Is the Expression of a General Dysregulation of the Immune Response, (2011) (2)
Screening for lupus anticoagulant: improving the performance of the lupus‐sensitive PTT‐LA (2011) (2)
[Severe hemorrhage, lymphocytosis and leukoerythroblastic blood picture--disseminated intravascular coagulation in metastatic prostate carcinoma and chronic lymphatic leukemia]. (1999) (2)
Mortality and Morbidities During Long-Term Follow-up After Recovery From Thrombotic Thrombocytopenic Purpura (TTP) (2012) (2)
International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) – Upshaw-Schulman Syndrome (2012) (2)
[Acute hyperkalemia and non-oliguric kidney failure during treatment with indomethacin, allopurinol, nifedipine, hydrochlorothiazide/amiloride, trimethoprim/sulfamethoxazole and acetylsalicylic acid]. (1988) (2)
In Vitro Effects of the Acylated StreptokinasePlasminogen Activator Complex BRL 33 575 Incubated with Normal Human Plasma (1984) (2)
[Still's disease in adults. 2 case reports]. (1983) (2)
[Fibrinolysis therapy in massive lung embolism. Experiences in 10 patients 1982-1984]. (1985) (2)
Plasmin Inhibitors and Fibrinogen Breakdown During the Initial Phase of Thrombolytic Treatment - The Problem of the α2-Antiplasmin Determination (1984) (2)
Polyendocrine deficiency syndrome. Occurrence in a patient with depressed IgA titers receiving phenytoin. (1980) (2)
Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: Another case of factor IX propeptide mutation (2011) (2)
Opana ER-induced thrombotic microangiopathy. (2017) (2)
[Increased thrombin time in a patient with multiple myeloma]. (1999) (2)
Variability of anti‐PF4/heparin antibody results obtained by the rapid testing system ID‐H/PF4‐PaGIA: reply to a rebuttal (2009) (2)
Stealth thrombosis of brain and kidney in a girl with Upshaw–Schulman syndrome not receiving prophylactic plasma infusions (2020) (2)
Control of Heparin Treatment with three Different Methods. Behaviour of Antithrombin III (1979) (2)
Prospective cross-sectional study of haemostatic factors in patients with and without coronary artery disease. (2003) (2)
[Internal bleeding in patients on oral anticoagulants]. (1993) (1)
[Factor VIII (coagulation activity VIII:C, antigen concentration VIIIR:Ag and von Willebrand factor) in patients with clinically expected intravascular coagulation]. (1981) (1)
Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature (2008) (1)
[The significance of APC resistance (activated protein C) for clinical practice]. (1997) (1)
Severe High Molecular Weight Kininogen (HK) Deficiency: Clinical Characteristics, Deficiency-Causing KNG1 Variants in Reported and New Cases, and Estimated Prevalence (2021) (1)
Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS. (2007) (1)
Prevalence of depression in patients with diagnosis of thrombotic thrombocytopenic purpura (TTP) (2015) (1)
[Life-long hemorrhagic diathesis in a young man with unclottable global coagulation tests--congenital afibrinogenemia]. (1999) (1)
[A frequent problem in the laboratory control of heparinization: contamination of blood specimens with exogenous heparin]. (1984) (1)
Apoptosis In Sepsis And Multiple Organ Dysfunction Syndrome (2004) (1)
Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature (2018) (1)
The Frequency of Rheumatic Disease Autoantibodies in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP). (2007) (1)
Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura (2021) (1)
The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency. (2004) (1)
[An infant with umbilical cord and intracranial hemorrhage--severe factor XIII deficiency]. (1999) (1)
[Derailed oral anticoagulation with very high INR values and poor response to oral vitamin K--cholestasis as a possible cause]. (1999) (1)
Definite diagnosis of plasma prekallikrein deficiency should not be based exclusively on shortening of the aPTT upon prolonged pre‐incubation (2022) (1)
Case 15: Chronic bleeding anemia and Osler’s disease (1999) (1)
Hemophagocytic Lymphohistiocytosis in Early Infancy- Pitfall of Differentiation between Hereditary and Infectious Reasons (2018) (1)
Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT). (2007) (1)
Polymerization of fibrin monomers results in increased thrombin binding (1990) (1)
antibodies kininogen in human plasma by immunoblotting with monoclonal Detection of in vitro and in vivo cleavage of high molecular weight (2011) (1)
Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera (2003) (1)
[Temporal arteritis in a patient with long-standing migraine]. (1988) (1)
[Systemic thrombolysis of arterial occlusions of the lower extremities. Comparison of various treatment schedules]. (1983) (1)
Malondialdehyde formation by blood platelets: a diagnostic test to assess acetylsalicylic acid induced thrombocytopathy? (1990) (1)
[Evaluating the origin of thrombophilia: indications and implementation]. (1992) (1)
Primärer Hyperparathyreoidismus — Semiquantitative Erfassung der Fibroosteoklasie und des Knochenumsatzes im Handröntgenbild (1979) (1)
Special Issue: “The Latest Clinical Advances in Thrombocytopenia” (2021) (0)
Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients (2018) (0)
Eleven Relapses in a Cohort of 78 Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Data from the German TTP-Registry (2019) (0)
Komplexe Gerinnungsstörungen (2010) (0)
Thrombophilia and outcomes of venous thromboembolism in older patients (2022) (0)
Prekallikrein Activator - Reply (1984) (0)
Hemostatic risk factors in ischemic stroke Franziska (2018) (0)
Inferior vena cava thrombosis in a child with nephroblastoma and combined deficiency of antithrombin III and free protein S (1990) (0)
DETECTION AND QUANTITATION OF CLEAVED AND UNCLEAVED HIGH MOLECULAR WEIGHT KININOGEN IN PLASMA BY LIGAND BLOTTING WITH RADIOLABELED PLASMA PREKALLIKREIN OR FACTOR XI (1987) (0)
Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults Following a Prodrome of Bloody Diarrhea. (2004) (0)
Circulating Nucleosomes Reflect Disease Activity in Patients with Thrombotic Microangiopathies. (2010) (0)
Thrombotic microangiopathies (2013) (0)
Das Bild der femme fatale im Film Noir am Beispiel der Filme "The Maltese Falcon" und "Double Indemnity" (2008) (0)
Are Patients Who Have Recovered From ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP) at Risk for Developing Systemic Lupus Erythematosus (SLE)? (2010) (0)
[Interaction: Modifast--oral anticoagulation]. (1983) (0)
More severe ADAMTS13 Deficiency in Homozygous versus Compound Heterozygous Carriers of the ADAMTS13 c.4143_4144dupA Mutation in Congenital Thrombotic Thrombocytopenic Purpura (cTTP): Impact on Disease Onset? (2019) (0)
Comments on 'Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody' by Reddigari and Kaplan. (1989) (0)
Endothelial Dysfunction, Atherosclerosis, and Increase of Von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine (2021) (0)
Neonatal exchange transfusion: hereditary thrombotic thrombocytopenic purpura (hTTP) should be in the differential diagnosis (2023) (0)
Pancreatitis Preceding Acute Episodes of Thrombotic Thrombocytopenic Purpura: Report of Five Patients with a Systematic Review of Published Reports. (2006) (0)
Rebuttal to the Letter of F. Rodeghiero et al. -Thrombosis in Subjects with Homozygous and Heterozygous Factor XII Deficiency (1992) (0)
COLD AGGLUTINING SYNDROME AND LIVER TRANSPLANTATION (1994) (0)
Le purpura thrombotique thrombocytopénique - un diagtnostic méconnu (2014) (0)
Rebuttal to the Letter to the Editor by W. P. M. Houdijk (1991) (0)
Laboratory studies on 8 platelet concentrates prepared by plateletcell™ separator (1990) (0)
Congratulations to Toshiyuki Miyata, PhD (2022) (0)
Long-Term Renal Outcomes in Hereditary TTP Patients: Data from the International Hereditary TTP Registry (2021) (0)
Title Pages / Table of Contents (2011) (0)
Continuing Medical Education Program in Transfusion (2012) (0)
Factor V Leiden Is Not a Risk Factor for Thrombotic Microangiopathies without Severe ADAMTS13 Deficiency. (2004) (0)
High Molecular Weight Kininogen Is Cleaved by FXIa at Three Sites: Arg409 -Arg410 , Lys502 -Thr503 and Lys325 -Lys326 (2017) (0)
Biological individuality and the new frontiers of immunological tolerance in hematopoietic stem cell transplantation (2010) (0)
THROMBOSIS AND HEMOSTASIS The splenic autoimmune response to ADAMTS 13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR 3 motifs (2014) (0)
ADAMTS13 Activity in Sickle Cell Disease: A Role in the Development of Clinical Vaso-Occlusion?. (2004) (0)
Case 7: APC resistance – the most frequent hereditary thrombophilia (1999) (0)
Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research (2021) (0)
[Primary hyperparathyroidism--bone turnover and osteitis fibrosa assessed by x-ray (author's transl)]. (1979) (0)
On the dosing of lepirudin. (2011) (0)
thrombotic thrombocytopenic purpura thrombocytopenic disorders: a severely deficient activity is specific for cleaving protease (ADAMTS13) in - Von Willebrand factor (2013) (0)
A third form of thrombotic thrombocytopenic purpura? (2022) (0)
Influence of Thrombotic Thrombocytopenic Purpura on Depressivity, Cognitive Conduction, Quality of Life, and Resilience of Patients (2020) (0)
in a prospective cohort of 142 patients uremic syndrome: relation to presenting features and clinical outcomes hemolytic - ADAMTS13 activity in thrombotic thrombocytopenic purpura (2013) (0)
Long-Term Outcomes of Renal Function in Patients with TTP Associated with Severe ADAMTS13 Deficiency (2011) (0)
Conclusion from 50 years of reports on prekallikrein or high-molecular-weight kininogen deficiency (2023) (0)
Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine (2015) (0)
P1528: GENETIC AND PHENOTYPIC CHARACTERIZATION OF HEREDITARY SPHEROCYTOSIS AND RELATED DISORDERS – DESCRIPTION OF 9 NEW GENETIC VARIANTS (2022) (0)
Hereditary thrombotic thrombocytopenic purpura and COVID‐19: Impacts of vaccination and infection in this rare disease (2022) (0)
Pearls, guidelines & more (2014) (0)
Chronically Elevated Interleukin-6 Disturbs the Coagulation Cascade in Mice (2021) (0)
Contents Vol. 33 (2003) (0)
[Pathophysiology and surgery of the parathyroid glands]. (1978) (0)
[APC resistance--most frequent familial thrombophilia]. (1999) (0)
Shifted Haemostatic Balance in Patients with Recurrent Venous or Arteral Thrombosis (1979) (0)
A Pathophysiological Role for ADAMTS13 in Thrombotic Thrombocytopenic Purpura (TTP) without Severe ADAMTS13 Deficiency. (2006) (0)
Severe high-molecular-weight kininogen deficiency: clinical characteristics, deficiency-causing KNG1 variants, and estimated prevalence. (2022) (0)
FACTOR XII, PLASMA PREKALLIKREIN ,α2-MACROGLOBULIN AND C1-INHIBITOR LEVELS IN RENAL ALLOGRAFT RECIPIENTS DURING IMMUNOSUPPRESSION WITH CYCLOSPORIN A (1987) (0)
[Thromboembolic diseases from the hematologic viewpoint: 13 case examples]. (1992) (0)
Founder Effect of the Factor-IX-Propeptide-Val-10 Variant Is Responsible for Most Marcumar-lnduced Severe Haemophilia B Cases During Oral Anticoagulant Therapy — Consequences for Monitoring (1999) (0)
Mi ta bisa – mi ta skirbi? – Komplexe Satzstrukturen einer Kreolsprache im Ausbau: Satzverknüpfungstechniken des Papiamentu auf Curaçao (2014) (0)
Acquired von Willebrand syndrome in a myeloproliferative disorder. Case 6. (2003) (0)
FACTOR VIII:C (F VIII:C) AND VON WILLEBRAND FACTOR ANTIGEN (vWFag) IN RENAL TRANSPLANT RECIPIENTS IMMUNOSUPPRESSED WITH CYCLOSPORIN A (CyA) (1987) (0)
[Venous thromboembolism in pregnancy and puerperium: pathophysiology, therapy, prevention]. (1991) (0)
VWF and complement. (2015) (0)
Absolute and Relative Blood Lymphocyte Subset Counts before and during Treatment of Patients with Thrombotic Thrombocytopenic Purpura (TTP). (2006) (0)
The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura (2023) (0)
Comment on “Worldwide Distribution of PK Deficiency: the Defect Seems Mainly Concentrated in West African Countries and the United States” (2021) (0)
Restricted Immunglobulin Gene Usage of Spleen-Derived Specific Anti-ADAMTS13 B-Cells In Relapsing TTP Treated with or without Rituximab. (2010) (0)
Thrombotic thrombocytopenic purpura and pregnancy (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Bernhard Lämmle?

Bernhard Lämmle is affiliated with the following schools:

Bernhard Lämmle's Academic­Influence.com Rankings

Bernhard Lämmle's Degrees

Similar Degrees You Can Earn

Why Is Bernhard Lämmle Influential?

Bernhard Lämmle's Published Works

Published Works

What Schools Are Affiliated With Bernhard Lämmle?

Bernhard Lämmle's AcademicInfluence.com Rankings